Search Results for "Brilinta Sales"

18:25 EDT 29th August 2014 | BioPortfolio

Original Source: Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets,...

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

Plavix

Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...

Matching News

AstraZeneca’s Brilinta Gives Brilliant Sales Performance

AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly i...

AstraZeneca Makes Progress on Global Brilinta Trial

AstraZeneca announced it has completed patient enrollment approximately four months ahead of plan in the Phase 3 clinical trial EUCLID studying Brilinta (ticagrelor) table

U.S. DoJ Clears AstraZeneca Over Brilinta PLATO Trial

AstraZeneca’s “all-clear” from the U.S. Department of Justice over Brilinta’s PLATO trial removes a dark cloud from the heart drug’s prospects and strengthens the pure pharma’s argument t...

US Ends Probe Into AstraZeneca’s Brilinta Without Charges

The US Department of Justice has closed without charges its ten-month investigation of British-Swedish AstraZeneca revolving around the blood thinner Brilinta. The probe into what the drugmaker regard...

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that it is closing its investigation into PLATO, a clinical trial with cardiovascular drug Brilinta (ti...

AstraZeneca bolsters defences with strong sales

AstraZeneca (LON:AZN) primed its defences against another assault from US pharma Pfizer by blasting past forecasts helped by a surge in sales of heart drug Brilinta. Sales rose by 4% to US$6.45bn (&po...

United States Department of Justice closes investigation into PLATO clinical trial for Brilinta

AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor)....

AZ gets all-clear in the USA over Brilinta data

AZ gets all-clear in the USA over Brilinta data

Matching PubMed Articles

Sellers, shakers, peddlers, and hawkers: rehabilitation of sales workers.

Sales workers persuade, influence, inform and cajole customers, resulting in the purchase of a product or service. The selling profession is broken down into three categories: sales technology, genera...

Variations in the sales and sales patterns of veterinary antimicrobial agents in 25 European countries.

To describe sales and sales patterns of veterinary antimicrobial agents in 25 European Union (EU)/European Economic Area (EEA) countries for 2011.

The effect of consignment to broodmare Sales on physiological stress measured by faecal glucocorticoid metabolites in pregnant Thoroughbred mares.

Validation of a method for the minimally-invasive measurement of physiological stress will help understanding of risk factors that may contribute to stress-associated events including recrudescence of...

Ticagrelor (brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.

Ariad suspends ponatinib sales.

Because of concerns about serious cardiovascular side effects, the U.S. Food and Drug Administration asked Ariad Pharmaceuticals to temporarily suspend sales and marketing of ponatinib to treat chroni...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement